Impact Therapeutics Targets 117 Million Dollars in HK IPO
The Chinese cancer-drug developer plans to offer 41.98 million shares at up to HK$21.75 each. Tencent is among the key investors for the May 13 listing.
Xurve View
洞察:
Xurve View
Impact Therapeutics aims to raise up to $117M in a Hong Kong IPO, according to a Tuesday morning term sheet. The China-based oncology firm is offering 41.98M shares priced between HK$19.75 and HK$21.75. This offering tests investor appetite for clinical-stage biotech as Singapore and regional hubs track listing volumes.
